Morgan Stanley initiated coverage on shares of ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) in a research note issued to investors on Thursday, The Fly reports. The brokerage issued an overweight rating on the stock.
Separately, ValuEngine raised shares of ASTELLAS PHARMA/ADR from a strong sell rating to a sell rating in a research report on Tuesday, December 3rd.
ALPMY stock traded up $0.22 on Thursday, reaching $17.35. 19,553 shares of the company were exchanged, compared to its average volume of 33,318. ASTELLAS PHARMA/ADR has a 12 month low of $12.77 and a 12 month high of $17.50. The stock’s fifty day moving average price is $17.13 and its 200 day moving average price is $15.43. The firm has a market capitalization of $32.77 billion, a PE ratio of 16.37 and a beta of 0.77.
About ASTELLAS PHARMA/ADR
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent.
Read More: What is a stock buyback?
Receive News & Ratings for ASTELLAS PHARMA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASTELLAS PHARMA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.